Long Term Follow-up Study With Levetiracetam XR (Keppra XR) for Partial Seizures
Information source: UCB
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Epilepsy
Intervention: Levetiracetam XR (Drug)
Phase: Phase 3
Status: Enrolling by invitation
Sponsored by: UCB Official(s) and/or principal investigator(s):
UCB Clinical Trial Call Center, MD, Study Director, Affiliation: +1 877 822 9493 (UCB)
Summary
To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term
safety of Keppra XR in patients with partial onset seizures.
Clinical Details
Official title: An Open-Label, Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Treatment of Partial-Onset Seizures
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Primary outcome: The primary endpoint is the evaluation of the long-term safety of Keppra XR in patients with partial onset seizures.
Eligibility
Minimum age: 12 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subjects who were randomized into study N01280 and completed the 2-week up titration
period
Exclusion Criteria:
- Subjects who did not meet the inclusion/exclusion criteria for N01280.
- Subjects who were discontinued prior to the end of titration period.
Locations and Contacts
Aguascalientes, Mexico
Monterey, Mexico
Gdansk, Poland
Poznan, Poland
Warszawa, Poland
Lodz, Poland
Katowice, Poland
Krakow, Poland
Bialystok, Poland
Northport, Alabama, United States
Dothan, Alabama, United States
Phoenix, Arizona, United States
Little Rock, Arkansas, United States
Loxahatchee, Florida, United States
Atlanta, Georgia, United States
Binghampton, New York, United States
Cedarhurst, New York, United States
Columbus, Ohio, United States
Toledo, Ohio, United States
Additional Information
Starting date: December 2007
Ending date: August 2009
Last updated: June 9, 2008
|
